Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 2, 2010, Pages 191-196

  Zuo, Chengguo ^a   Wen, Feng ^a   Li, Jiaqing ^a   Liu, Yan ^a   Long, Shixian ^a   Huang, Shizhou ^a   Li, Meng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Color vision; Contrast sensitivity; Intravitreal bevacizumab; Photodynamic therapy; Polypoidal choroidal vasculopathy

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR DISCRIMINATION; COLOR VISION TEST; CONTRAST SENSITIVITY; DRUG EFFECT; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISCRIMINATION; VISUAL IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COLOR PERCEPTION TESTS; COLOR VISION; CONTRAST SENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; THERAPEUTICS; VISUAL ACUITY; VITREOUS BODY;

EID: 77949271491     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1210-7     Document Type: Article

References (28)

1. LA Yannuzzi A Ciardella RF Spaide M Rabb KB Freund DA Orlock 1997 The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy Arch Ophthalmol 115 478 485 1:STN:280:DyaK2s3mtlyrtg%3D%3D 9109756
2. LA Yannuzzi J Sorenson RF Spaide B Lipson 1990 Idiopathic polypoidal choroidal vasculopathy (IPCV) Retina 10 1 8 10.1097/00006982-199001010-00001 1:STN:280:DyaK3c3mtVequw%3D%3D 1693009 (Pubitemid 20201879)
3. Y Kurashige A Otani M Sasahara Y Yodoi H Tamura A Tsujikawa N Yoshimura 2008 Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy Am J Ophthalmol 146 513 519 10.1016/j.ajo.2008.05.025 18614133
4. SY Lee JG Kim SG Joe H Chung YH Yoon 2008 The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy Korean J Ophthalmol 22 92 99 10.3341/kjo.2008.22.2.92 18612226
5. TY Lai WM Chan DT Liu FO Luk DS Lam 2008 Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy Br J Ophthalmol 92 661 666 10.1136/bjo.2007.135103 1:STN:280:DC%2BD1c3ns1ChtA%3D%3D 18356265 (Pubitemid 351684177)
6. F Gomi M Sawa H Sakaguchi M Tsujikawa Y Oshima M Kamei Y Tano 2008 Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 92 70 73 10.1136/bjo.2007.122283 1:STN:280:DC%2BD2sjlvFyltQ%3D%3D 17567661
7. M Mauget-Faysse M Quaranta-El Maftouhi E De La Marnierre A Leys 2006 Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy Eur J Ophthalmol 16 695 704 1:STN:280:DC%2BD28nis1Citw%3D%3D 17061220
8. M Quaranta M Mauget-Faysse G Coscas 2002 Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin Am J Ophthalmol 134 277 280 10.1016/S0002-9394(02)01516-7 12140043 (Pubitemid 34831840)
9. E Stifter S Sacu A Thaler H Weghaupt 2006 Contrast acuity in cataracts of different morphology and association to self-reported visual function Invest Ophthalmol Vis Sci 47 5412 5422 10.1167/iovs.05-1564 17122131 (Pubitemid 46723792)
10. IU Scott WJ Feuer JA Jacko 2002 Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration Am J Ophthalmol 133 350 357 10.1016/S0002-9394(01)01406-4 11860972 (Pubitemid 34171585)
11. N Bansback C Czoski-Murray J Carlton G Lewis L Hughes M Espallargues C Brand J Brazier 2007 Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity Qual Life Res 16 533 543 10.1007/s11136-006-9126-8 1:STN:280:DC%2BD2s7jtlKlug%3D%3D 17119846 (Pubitemid 46363686)
12. RS Moorthy AT Lyon MF Rabb RF Spaide LA Yannuzzi LM Jampol 1998 Idiopathic polypoidal choroidal vasculopathy of the macula Ophthalmology 105 1380 1385 10.1016/S0161-6420(98)98016-2 1:STN:280:DyaK1cznsFCktQ%3D%3D 9709746 (Pubitemid 28509753)
13. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group 1999 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report Arch Ophthalmol 117 1329 1345
14. PR Kinnear 1970 Proposals for scoring and assessing the 100-Hue test Vis Res 10 423 433 10.1016/0042-6989(70)90123-9 1:STN:280:DyaE3M%2Fjs1Oksw%3D%3D 5312357
15. O Tatar E Kaiserling A Adam F Gelisken K Shinoda M Volker BA Lafaut KU Bartz-Schmidt S Grisanti 2006 Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes Arch Ophthalmol 124 815 823 10.1001/archopht.124.6.815 1:CAS:528:DC%2BD28XmtlWnur0%3D 16769835 (Pubitemid 43877675)
16. O Tatar A Adam K Shinoda P Stalmans C Eckardt M Luke KU Bartz-Schmidt S Grisanti 2006 Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy Am J Ophthalmol 142 95 104 10.1016/j.ajo.2006.01.085 1:CAS:528:DC%2BD28Xms1Gkurw%3D 16815256 (Pubitemid 43949615)
17. CH Meyer DJ Lapolice S Fekrat 2005 Functional changes after photodynamic therapy with verteporfin Am J Ophthalmol 139 214 215 10.1016/j.ajo.2004.07.034 15652863 (Pubitemid 40094876)
18. A Kumar K Gopalakrishnan S Sinha 2008 Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study Retina 28 1132 1137 10.1097/IAE.0b013e318170d76d 18779720
19. RV Azad MA Khan B Chanana S Azad 2008 Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population Jpn J Ophthalmol 52 52 56 10.1007/s10384-007-0496-4 1:CAS:528:DC%2BD1cXkvVals78%3D 18369701
20. F Ziemssen M Luke KU Bartz-Schmidt F Gelisken 2008 Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation) Graefes Arch Clin Exp Ophthalmol 246 653 659 10.1007/s00417-007-0726-y 18071731
21. V Chaudhary A Mao PL Hooper TG Sheidow 2007 Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial Ophthalmology 114 2183 2189 10.1016/j.ophtha.2007.02.013 18054638 (Pubitemid 350181099)
22. KM Rocha ES Soriano MR Chalita AC Yamada K Bottos J Bottos L Morimoto W Nose 2006 Wavefront analysis and contrast sensitivity of aspheric and spherical intraocular lenses: a randomized prospective study Am J Ophthalmol 142 750 756 10.1016/j.ajo.2006.06.031 17056359 (Pubitemid 44584154)
23. C Owsley ME Sloane 1987 Contrast sensitivity, acuity, and the perception of 'real-world' targets Br J Ophthalmol 71 791 796 10.1136/bjo.71.10.791 1:STN:280:DyaL1c%2FltVKltw%3D%3D 3676151
24. MF Marmor A Gawande 1988 Effect of visual blur on contrast sensitivity. Clinical implications Ophthalmology 95 139 143 1:STN:280:DyaL1c7ktlGksQ%3D%3D 3344122
25. J Sjostrand 1979 Contrast sensitivity in macular disease using a small-field and a large-field TV-system Acta Ophthalmol (Copenh) 57 832 846 10.1111/j.1755-3768.1979.tb01851.x 1:STN:280:DyaL3c7gsF2qtw%3D%3D
26. L Hyvarinen P Laurinen J Rovamo 1983 Contrast sensitivity in evaluation of visual impairment due to macular degeneration and optic nerve lesions Acta Ophthalmologica 61 161 170 10.1111/j.1755-3768.1983.tb01409.x 1:STN:280:DyaL3s3nvVOqsg%3D%3D 6880629
27. S Mitra 1985 Spatial contrast sensitivity in macular disorder Doc Ophthalmol 59 247 267 10.1007/BF00159263 1:STN:280:DyaL2M3ivF2lsg%3D%3D 4006670 (Pubitemid 15111897)
28. F Ziemssen M Luke A Messias J Beutel O Tatar E Zrenner KU Bartz-Schmidt 2008 Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients Int Ophthalmol 28 101 109 10.1007/s10792-007-9122-1 17634860